Human butyrylcholinesterase - PharmAthene

Drug Profile

Human butyrylcholinesterase - PharmAthene

Alternative Names: NEX 91; Protexia; rBChE; rBChE bioscavenger; Recombinant human butyrylcholinesterase

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator PharmAthene
  • Class Antidotes; Butyrates; Cholinesterases
  • Mechanism of Action Scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Poisoning

Highest Development Phases

  • No development reported Alzheimer's disease; Poisoning

Most Recent Events

  • 08 Sep 2014 Human butyrylcholinesterase - PharmAthene is available for licensing as of 08 Sep 2014.
  • 08 Sep 2014 PharmAthene and Nanotherapeutics sign agreement for advancing the development of medical countermeasures for the US biodefense market
  • 09 Jan 2014 Research is ongoing USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top